Clinical trial
Efficacy and Safety Study of Oral Fludarabine Phosphate in Combination With…
NCT00185445 · Genzyme, a Sanofi Company, Industry · Completed
Key facts
| NCT number | NCT00185445 |
|---|---|
| Title | Efficacy and Safety Study of Oral Fludarabine Phosphate in Combination With Mitoxantrone as First Line Treatment in Follicular NHL |
| Official title | A Phase II Study to Evaluate the Efficacy and Safety of Oral Fludarabine Phosphate in Combination With Mitoxantrone as First Line Treatment in Follicular NHL |
| Lead sponsor | Genzyme, a Sanofi Company, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Non Hodgkin Lymphoma |
| Intervention type | Drug |
| Interventions | Fludarabine Phosphate (Fludara) |
| Enrollment | 62 |
| Start date | Jun 1, 2004 |
| Primary completion | Oct 1, 2006 |
| Completion | Oct 1, 2006 |
| First posted | Sep 16, 2005 |
| Last update posted | Dec 4, 2013 |
| Countries | Italy |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: